Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 1, 2026

Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more

View original at seekingalpha.com
Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more [February 2026 Yellow Desk Calendar Among Office Supplies] spawns/iStock via Getty Images Earnings season rolls into a high-impact week ahead, with results due from a broad cross-section of the market spanning Big…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Philip Morris strong execution has driven a 108% total return since January 2024, more than double the S&P 500

    80% confidence
  • PFE trades at just ~8.5x forward non-GAAP earnings, well below peers such as AbbVie, Merck, and Eli Lilly, while offering a dividend yield north of 6%

    80% confidence
  • Amazon remains a Strong Buy with a $319.56 price target and 32% upside, despite recent underperformance versus the S&P 500

    80% confidence
  • Valuation multiples sit at multi-decade highs, with EV/EBITDA near 26x and FCF yield compressed to ~1.8%

    80% confidence
  • Disney remains a Buy with strong FY26-FY27 EPS growth guidance and attractive valuations suggesting meaningful upside

    80% confidence
  • Alphabet is a Buy with a $331 price target, pointing to accelerating Gemini AI adoption and expanding Google Cloud margins

    80% confidence
  • Pfizer maintains a Sell rating citing persistent margin and growth headwinds

    80% confidence
  • Applying a conservative 16.5x EV/EBITDA multiple, AMZN still offers attractive upside, with margins and free cash flow expected to improve by 2026

    80% confidence
  • Pfizer remains firmly in the green zone into 2026, with the bullish case resting on oncology and vaccine pipeline alongside potentially best-in-class GLP-1/amylin candidates

    80% confidence
  • While PM now trades closer to fair value, further upside hinges on upgraded guidance, supporting a continued Buy stance

    80% confidence
  • Expectations are building for higher capital deployment (~$29B) and potentially ~44% growth in Google Cloud in early 2025

    80% confidence
  • Alphabet downgraded to Hold, noting that shares have nearly doubled in a year and appear fully priced

    80% confidence
  • Pfizer's 2026 guidance implies continued Y/Y declines, with revenue and EPS midpoints of $61B and $2.90, respectively

    80% confidence
  • The rally has been driven primarily by robust ZYN growth, with nicotine pouch volumes up 36% Y/Y

    80% confidence
  • Amazon is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum, and improving DTC fundamentals

    80% confidence
  • Philip Morris reaffirmed its FY2025 profit guidance at Morgan Stanley Global Consumer & Retail Conference in December

    80% confidence
  • Disney is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum from franchises like Avatar and Zootopia 2, and improving DTC fundamentals driven by subscriber growth and expanding ARPUs

    80% confidence

Data points we hold from this source

The Walt Disney Company · revenue25.60 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more — Source | Via News | ViaNews Market